Diffuse large B–cell lymphoma (DLBCL) is the most common subtype of non–Hodgkin’s lymphoma. Differences in treatment outcomes likely relates to genetic heterogeneity within DLBCL. BCL6 gene rearrangement is the most common cytogenetic abnormality in DLBCL, but the effect of the BCL6 rearrangement on outcome has remained uncertain. In our study we analyzed BCL6 gene translocation t (3;14) (q27;q32) in 22 patients with DLBCL as a prognostic marker. There was statistically significant worse overall survival in the group of patients without translocation. Analyzed translocation could be potentially useful prognostic marker for identifying the poor prognosis for DLBCL patients.